FDA guidance says sponsors should provide 'convincing' proof of concept data to support INDs for individualized medicine
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyClinical TrialsNorth AmericaPreclinical studyRegulatory Intelligence/Policy